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Aims As health systems around the world increasingly look to measure and improve the value of care that they provide to
patients, being able to measure the outcomes that matter most to patients is vital. To support the shift towards value-
based health care in atrial fibrillation (AF), the International Consortium for Health Outcomes Measurement (ICHOM)
assembled an international Working Group (WG) of 30 volunteers, including health professionals and patient represen-
tatives to develop a standardized minimum set of outcomes for benchmarking care delivery in clinical settings.
...................................................................................................................................................................................................
Methods
and results
Using an online-modified Delphi process, outcomes important to patients and health professionals were selected
and categorized into (i) long-term consequences of disease outcomes, (ii) complications of treatment outcomes,
and (iii) patient-reported outcomes. The WG identified demographic and clinical variables for use as case-mix risk
adjusters. These included baseline demographics, comorbidities, cognitive function, date of diagnosis, disease dur-
ation, medications prescribed and AF procedures, as well as smoking, body mass index (BMI), alcohol intake, and
physical activity. Where appropriate, and for ease of implementation, standardization of outcomes and case-mix
variables was achieved using ICD codes. The standard set underwent an open review process in which over 80%
of patients surveyed agreed with the outcomes captured by the standard set.
...................................................................................................................................................................................................
Conclusion Implementation of these consensus recommendations could help institutions to monitor, compare and improve
the quality and delivery of chronic AF care. Their consistent definition and collection, using ICD codes where ap-
plicable, could also broaden the implementation of more patient-centric clinical outcomes research in AF.
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Introduction
Atrial fibrillation (AF) is an increasingly prevalent clinical and public
health problem, affecting more than 33 million people worldwide1
and predicted to affect nearly 18 million people in Europe alone by
2060.2 Atrial fibrillation is associated with adverse health outcomes,
poor health-related quality of life (HRQoL), and high healthcare costs
with hospitalization being the main cost driver.3 The goals of any
health care provider managing patients with AF should be:
• to improve HRQoL, including alleviating symptoms and conse-
quent problems such as treatment burden and anxiety;
• to reduce the risk of long-term sequelae, i.e. systemic embolism,
stroke, or heart failure;
• to reduce mortality; and
• to deliver care in a cost-sensitive manner.
Currently, significant variation exists in AF care and treatment
practices between institutions and countries.4,5 The 2017 Lancet
Global Burden of Disease study estimated that non-communicable
diseases account for 73% of all deaths globally,6 of which over half are
attributable to four cardiovascular risk factors (hypertension, smok-
ing, diabetes mellitus, and obesity). The largest number of deaths
from non-communicable diseases was from cardiovascular diseases.
Efforts to address preventable cardiovascular morbidity and mortal-
ity, therefore, should be enhanced and encouraged.6
The notion of ‘value’ in healthcare has taken on increasing import-
ance over the last 15 years. Value may be defined within the health-
care context as patient-relevant outcomes divided by the costs per
patient across the full cycle of care.7 As healthcare systems world-
wide work to improve the value of care that they provide to patients,
particularly in the context of growing demands on providers amid sig-
nificant resource constraints, being able to measure outcomes im-
portant to patients is crucial.8 Although clinicians gather more data
today than ever before, what is measured may have little relationship
to the goals of healthcare that matter most to patients. The ability to
define ‘value’ in healthcare is, therefore, not straightforward.
A challenge related to value in healthcare is that its measurement
relies on the validity and robustness of measurements. A good source
of robust clinical outcomes and their definitions is found in clinical tri-
als and in the output of major registries. Efforts to report outcomes
of routine AF care exist already. For example, there are a number of
large registries reporting on thromboprophylaxis and stroke preven-
tion,9–11 some that report on antiarrhythmic drug therapy and cardi-
oversion,12–15 and a few on ablation.16–18 Some international
societies have produced position papers and guidelines in an attempt
to standardize care across their jurisdictions.19–21 Although several
position papers have been published attempting to do so,22,23 there
is no single internationally accepted standardized approach to report
outcomes of care in AF. A fully standardized approach would include
both the outcomes that are measured as well as the process of meas-
urement and recording, e.g. using electronic health records. While
survival or hospitalization outcomes are frequently recorded,
patient-reported outcomes are still rarely measured and/or recorded
despite increasing recognition of their importance in disease manage-
ment.24,25 The lack of a standardized approach hinders routine moni-
toring and benchmarking of different clinical practices. To support
the development of a standardized outcome set in AF for integration
into routine clinical practice, the International Consortium for Health
Outcomes Measurement (ICHOM) convened an international multi-
disciplinary Working Group (WG) of experts and patient represen-
tatives. As a not-for-profit organization, ICHOM has developed 27
standard sets of value-based outcomes for use in routine clinical prac-
tice in various medical conditions, such as coronary artery disease,26
stroke,27 and cancer (including breast,28 colorectal,29 and prostate
cancer30). Over 600 organizations have implemented ICHOM sets
including 15 national registries. Standard sets are reviewed and
updated annually by ICHOM.
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The aim of the project was to propose a standardized minimum
set of outcomes for AF, including patient-reported outcomes, and
case-mix factors, for comparisons across treatment modalities and
institutions.
Methods
Composition of the working group
ICHOM established a geographically diverse WG covering a broad range
of sub-specialties within the AF community. The WG consisted of 30
members, including clinicians, registry experts, epidemiologists, research
scientists, and six patients and patient representatives from 11 countries
in Europe, North America, Latin America, the Middle East, and Asia-
Pacific. Twenty percent of WG members were either AF patients or rep-
resented AF patient organizations. Two of the patient representatives in
the WG represented the two largest AF patient organizations globally.
A project team (W.H.S., Z.D.-G., A.J.-O., and A.J.C.) guided the efforts of
the WG.
Development of the atrial fibrillation
standard set
The WG convened using seven teleconferences between January 2018
and March 2019, following a structured process similar to that of previous
ICHOM WGs (Supplementary material online, Item S1). The develop-
ment of the standard set involved several phases: defining the scope of
the project; prioritizing and defining outcome domains; evaluating and
selecting outcome measures that would be used to measure the out-
come domains, including clinical data and patient-reported outcome
measures (PROMs); and selecting and defining case-mix variables.
Identification of potential outcomes and
case-mix variables
The project team performed a systematic literature review, following
Preferred Reporting Items for systematic Reviews and Meta-Analyses
(PRISMA) guidelines to identify potential outcome domains, PROMs, and
case-mix variables. The search strategy is included in a supplement to this
article (Supplementary material online, Item S2). This search retrieved
2121 articles. The 100 most recent PubMed-indexed articles published as
of 1 March 2018 were subsequently included for review.
Atrial fibrillation registries were reviewed to extract additional out-
come measures and case-mix adjustment variables. These registries were
identified from a systematic review by Mazurek et al.31 and by internet
searches. Some of these registries were specifically designed to assess
outcomes that had previously been reported in clinical trials. Patient rep-
resentatives from the WG participated as a patient advisory group in a
separate breakout session in order to explore their perspectives on the
importance of different outcomes. An additional literature review was
performed to identify studies of patients’ perspectives on the most rele-
vant outcome domains in AF.
Consensus process
Following each teleconference, the project team circulated an electronic
survey to the WG to gather feedback on each key decision. An online
three round modified Delphi process was performed for selection of out-
comes, following the RAND/University of California (Los Angeles) meth-
odology32 and based on a literature review,33 to achieve consensus on
which outcomes should be included. Inclusion in the standard set
required that at least 80% of the WG voted an item as ‘essential’ (score
7–9 on a 9-point Likert scale) in either voting round. Outcomes were
excluded if at least 80% of the WG voted an item as ‘not recommended’
(Score 1–3). The WG voted on all inconclusive outcome domains in the
final third round with 70% consensus required for the domain to be
included (yes/no scale).
Selection of patient-reported outcome
measures
After the outcomes were chosen for inclusion in the standard set, corre-
sponding PROMs were identified from the literature and registry review.
The original and validation studies of the instruments were examined in
order to evaluate the psychometric quality, domain coverage, and feasibil-
ity of measurement and implementation. An advisory group consisting of
academics and patients with particular expertise in PROMs in AF was
convened in a breakout session in order to review the list of potential
instruments compiled by the project team.
A similar process was used to agree on which PROM tools and case-
mix variables should be recommended. The results of each vote were
reviewed by the WG at the subsequent teleconference. The criteria by
which outcome domains were assessed for inclusion in the set were: (i)
frequency of the outcome, (ii) impact on the patient, (iii) potential for
modifying the outcome, and (iv) feasibility of measuring the outcome.
Variables to be used as case-mix adjusters were assessed on: (i) rele-
vance, (ii) independence, and (iii) the measurement feasibility.
Open review
Atrial fibrillation patients, recruited via professional associations
(Arrhythmia Alliance and StopAfib.org) reviewed the final draft of the
standard set, and independently provided feedback using an online survey
that was shared by the associations through email and social media.
Respondents were asked to rate their confidence regarding several ele-
ments of the set on a 9-point Likert scale34 (1 not important, 5 somewhat
important, 9 most important), with an open field for comments.
Results
Scope
The outcomes and measures included in the AF standard set were
defined for a target population of adult patients, 18 years and older,
diagnosed with AF; including patients with asymptomatic AF.
Cardiotoxic AF (e.g. acute AF related to drugs and/or toxic substan-
ces) was excluded. The treatment approaches covered are catego-
rized: management of cardiovascular risk factors and initiation of
preventive therapy (e.g. lifestyle interventions and patient education);
pharmacological management (e.g. rate control, rhythm control and
anticoagulants); and non-pharmacological management (e.g. pace-
maker, DC cardioversion, catheter-based atrial ablation, surgical abla-
tion, atrioventricular node ablation, catheter-based left atrial
appendage occlusion, and left atrial appendage excision/exclusion).
Outcomes
Through the literature review, registry search and patient advisory
group discussions, the WG selected 18 outcome domains. The
Reference Guide containing all consensus definitions is published on
the ICHOM website at www.ichom, org. The outcome domains
were categorized into three major groups: long-term consequences
of disease, complications of treatment, and patient-reported out-
comes (Table 1). The results of the Delphi process are shown in
Supplementary material online, Item S3.
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Table 1 Summary of ICHOM atrial fibrillation standard set of outcomes
Domain Measure Details Timing Data source
Long-term
consequences of
disease
Mortality (all-cause and
cardiovascular)
Cardiovascular cause of deatha Ongoing Clinician
Ischaemic stroke, systemic embolism,
and unclassified stroke
Occurrence of a cardiovascular eventb
Heart failure Clinical diagnosis of heart failure and value of
LVEFc
Cardiovascular hospitalization Hospital admissiond due to an unplanned car-
diovascular causee
Freedom from fast atrial arrhythmia
post-treatment
Detection of fast atrial arrhythmia and mode of
treatmentf and monitoringg administered
Anticoagulation management Rationaleh for prescribing anticoagulation ther-
apy and prescription of a treatment devicei
1–6 months and 1
year
Cognitive functioning Assessment of cognition
Complications of
treatment
Haemorrhagic stroke Occurrence of a cardiovascular eventb Ongoing
Life-threatening/major bleeding Occurrence of fatal bleeding, symptomatic
bleeding in a critical area or organ,j and/or fall
in haemoglobink
Serious adverse events post-
intervention
Occurrence of serious adverse eventsl due to
an interventionm
Medication side effects Occurrence of medication side effectn that led
to discontinuing of prescribed medicationo
Patient-reported
outcomes
Health-related quality of life Measured with the SF-12 VR or the PROMIS
Global Health VR
1–6 months and 1
year
Patient
Physical functioning
Emotional functioning
Exercise tolerance Measured with the AFEQTp or the AFSSq
Symptom severity
Ability to work Measured with the WPAIr
Cognitive functioning Measured with the PROMIS Cognitive
FunctionVR
aAn acute myocardial infarction; sudden cardiac death; heart failure; stroke; cardiovascular procedure; cardiovascular haemorrhage; other cardiovascular causes, e.g. peripheral
arterial disease; other cause of death; unknown.
bAn ischaemic stroke; a systemic embolism; an unclassified stroke; none of above. Date (DD/MM/YYYY).
cLeft ventricular ejection fraction (LVEF).
dAdmission = at least one overnight stay at a hospital or acute care facility from first atrial fibrillation diagnosis.
eCardiovascular causes for admission are ones in which the principal admitting diagnosis relates to the cardiovascular system: myocardial infarction/ischaemic heart disease,
heart failure, stroke/TIA, peripheral arterial disease, AF, venous thromboembolism/PE, etc.
fRate control drugs; pharmacological cardioversion; electrical cardioversion; atrial ablation; AVN/His-bundle ablation; surgical atrial ablation; pacemaker.
gA 12-lead ECG; ambulatory monitoring; implantable devices; wearable devices/smartphones.
hNot recommended by current guidelines. Anticoagulants are not appropriate for beneficial reasons, e.g. young patient with no underlying heart conditions; Not recommended
by current guidelines; anticoagulants inappropriate for harmful reason or due to harm reasons, e.g. patients with serious bleeding events; patient refusal; medication and/or mon-
itoring/follow-up unavailable; cognitive dysfunction; short life expectancy; high costs (including health insurance issue); other (specify).
iLeft atrial appendage occlusion device, closure or excision of the left atrial appendage.
jIntracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial, or intramuscular with compartment syndrome.
kHaemoglobin >2 g/dL or transfusion of >2 units of whole blood/red cells.
lIn hospital death; vascular complications (postoperative haemorrhage, postoperative haemorrhage requiring transfusion, pericardial tamponade); required open heart surgery;
required repeat ablation procedure; ventricular arrhythmias; respiratory complications(pneumothorax; phrenic nerve palsy; pulmonary vein stenosis; other iatrogenic respira-
tory complications); trauma embolic complications, stroke, TIA, systemic or pulmonary embolism; postprocedure infections; atrio-oesophageal fistula; other (specify).
mCatheter-based ablation (four subcategories); surgical ablation procedure (including MAZE); hybrid catheter and surgical ablation; left atrial appendage closure/occlusion (de-
vice); left atrial appendage ligation/excision (surgical); electrical cardioversion; pacemaker implantation; pharmacological cardioversion.
nDizziness, fainting, lightheadedness, or loss of consciousness; erectile dysfunction; hair loss; memory problems, brain for or poor concentration; mental health issues such as de-
pression or anxiety; muscle or joint pain; shortness of breath; stomach problems such as nausea, vomiting or diarrhoea; unexplained bruising or bleeding; unusual weakness or
tiredness; weight loss; other (specify).
oAntithrombotic (anticoagulation, antiplatelet) rhythm control; rate control; other (specify); unknowns.
pAtrial Fibrillation Effect on Quality-of-Life Questionnaire.
qUniversity of Toronto Atrial Fibrillation Severity Scale.
rWork Productivity and Activity Impairment Questionnaire: General Health V2.0.
4 W.H. Seligman et al.
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Long-term consequences of disease
This outcome domain consists of the following sub-domains: mortal-
ity (all-cause and cardiovascular); ischaemic stroke, systemic embol-
ism, unclassified stroke; heart failure; cardiovascular hospitalization;
freedom from rapid and/or symptomatic atrial arrhythmia post-
treatment; anticoagulation management; clinician-reported patient
cognitive functioning.
Complications of treatment
Complications of AF treatment selected for inclusion were:
haemorrhagic stroke, life-threatening/major bleeding, serious ad-
verse events post-intervention, and medication side effects; all
of which were highly ranked by patients during the patient ad-
visory group discussion. Building upon the International Society
on Thrombosis and Haemostasis definition for bleeding, the
WG expanded the definition by specifying, ‘bleeds that require
medical intervention by healthcare professional, leading to hos-
pitalization or increase in the level of care, or prompting a face-
to-face evaluation’.
Patient-reported outcomes
As the primary aim of the standard set is to measure outcomes that
matter most to patients with AF, the WG recommended specific
patient-reported outcomes. The following sub-domains were
selected: HRQoL, emotional functioning, physical functioning, exer-
cise tolerance, symptom severity, ability to work, and cognitive
functioning.
Baseline characteristics and case-mix
variables
In addition to the outcome measures, the WG selected important
baseline health characteristics that are important to collect to enable
....................................................................................................................................................................................................................
Table 2 Summary of ICHOM atrial fibrillation standard set case-mix variables
Category Measure Details Timing Data source
Case-mix variables Demographic factors Age Year of birth Baseline Patient
Sex Sex at birth
Level of education Highest attained educationa
Ethnicity (optional) Country specific
Lifestyle interventions Smoking status Never/former/current Baseline and annually Clinician/
administrativeBMI BMI (height and weight)b
Alcohol intake Number of standard alcoholic
drinks do you drink per weekc
Patient
Physical activity Frequency of engagement in
moderate to strenuous
exercised
Patient/clinician
Baseline health status Comorbidities Indicate whether the patient has
a documented history or is
currently diagnosede
Baseline at the time of
diagnosis
Clinician
Cognitive function Measured with the MoCAf Baseline
Diagnosis Types of atrial fibrillationg Baseline and annually
Disease duration Diagnosis dateh
Medications
prescribed
Indicate whether the patient is
currently being prescribed
medication for atrial
fibrillationi
Procedure type Eight broad categoriesj
aISED classification (none/primary/secondary/tertiary).
bBMI <18.5 underweight; 18.5–24.9 normal weight; 25–29.9 pre-obesity; and >30.0 obesity.
cOptions: none; 1–6; 7–14; >14. Supporting definition: standard drink according to WHO is 20 g of pure alcohol that is: a can or bottle of beer (375 mL or 12 oz at 3.5% alcohol
by volume) or a small glass of red wine (100 mL or 3–4 oz at 13% alcohol by volume) or a shot of whiskey or other spirit (30 mL or 1 oz at 40% alcohol by volume).
dMeasured by the physical activity vital sign.
eAnswer (yes/no): gastrointestinal/other major haemorrhage, intracranial haemorrhage; hypertension; diabetes mellitus; heart failure; ischaemic heart disease/myocardial infarc-
tion; vascular diseases, e.g. coronary disease, arterial disease; chronic obstructive pulmonary disease; chronic kidney disease; hyperthyroidism; obstructive sleep apnoea; stroke/
TIA; cancer (excluding non-melanoma skin cancer).
fThe Montreal Cognitive Assessment.
gParoxysmal (episode of AF that terminates spontaneously or with intervention in <7 days); persistent (AF that lasts for >7 days and requires intervention in order for cardio-
version to occur); long-standing persistent (episodes of AF extending >12 months); permanent (AF that will not be cardioverted or has failed cardioversion).
hAnswer options: diagnosed date (DD/MM/YYYY); recent (less than a year and date unknown); unknown.
iThree major categories with sub-options: antithrombotic agents (two subcategories); rate control agents (four subcategories); rhythm control agents (four subcategories).
jCatheter-based ablation (four subcategories); surgical ablation procedure (including MAZE); hybrid catheter and surgical ablation; left atrial appendage closure/occlusion (de-
vice); left atrial appendage ligation/excision (surgical); electrocardioversion; pharmacological cardioversion; pacemaker implantation.
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.comparison between providers. These baseline health characteristics
include demographics, comorbidities, cognitive function, date of diag-
nosis, disease duration, medications prescribed, and procedure type.
The WG also identified lifestyle intervention variables that may affect
the management and care of patients with AF and influence their out-
comes, including smoking, BMI, alcohol intake, and physical activity
(Table 2).
Open review
An electronic survey was distributed to AF patients via patient net-
works through email and social media. Four hundred and eighty-nine
respondents replied electronically to the validation survey seeking
feedback on the outcomes included in the standard set. The majority
(87%) of respondents agreed that the standard set captures all the
important outcomes. All patient-reported outcomes were rated as
very important, with a range from 83% for ability to work to 95% for
physical functioning (Figure 1). The additional outcomes that respond-
ents suggested adding to the standard set included mental health im-
pact such as depression, anxiety, feeling worried and stressed, and
the health literacy domain that included aspects such as patient–clin-
ician communication, disease understanding, treatment options
knowledge, and empowerment to control disease. The WG agreed
to include the emotional functioning domain in the core set but
decided to exclude the health literacy domain as it covers aspects
outside of the scope of the current project.
Discussion
In this project, an international WG comprising AF experts, patients
and patient representatives, developed a consensus set of the most
important outcomes and outcome measures in AF. The production
of such a standard set could help institutions to monitor, compare
and improve the quality and delivery of chronic AF care. The WG
also defined a set of case-mix variables that must be adjusted for
when comparing outcomes across institutions or regions. This is the
first global effort to develop a standardized minimum set of patient-
centred outcomes in AF for use in clinical practice.
The approach taken in this project goes some way to supporting
the principles of value-based healthcare and a value-based outcomes
framework. Value-based healthcare has the potential to benefit stake-
holders across the healthcare spectrum.35 For example, patients
could in future choose providers based on informed expectations of
outcomes and the associated costs.36 Providers that deliver superior
outcomes at competitive costs may excel, while others are forced to
improve or lose market share. Equally, payers could negotiate con-
tracts based on results and encourage innovation to achieve those
results.37 The life science community could succeed by marketing its
products based on value, showing improved patient outcomes rela-
tive to costs. While additional work above and beyond a consensus
process would be required to reach these aspirations, nevertheless a
consensus process can identify areas of importance for future aca-
demic research, e.g. PROMs in AF. Indeed, one of the recommenda-
tions of the WG was that there is a need to develop and validate
further AF-specific PROMs. The WG acknowledges that other
PROMs could have been selected for inclusion in the standard set,
however, those ultimately included were considered to be the most
appropriate tools currently available.
The ability to measure outcomes most relevant to patients in a
standardized manner globally is key to unlocking the potential of
value-based health care.38 By establishing a geographically and clinical-
ly diverse WG of AF patients and experts in AF, we have developed a
Figure 1 Relevance of outcomes included in ICHOM AF set according to patient open review.
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minimum set of outcomes for AF, focused on patient-centred meas-
ures, that could be recorded in routine clinical practice. This may sup-
port the shift towards value-based health care in AF.8
Our literature review of recent randomized clinical trials in AF
revealed heterogeneity in outcomes. Nevertheless, there was over-
lap in outcomes collected by trials, registries, and those reported by
patients. This is unsurprising given that some registries are designed
to assess outcomes previously reported in clinical trials. Prioritizing
the outcomes that would feature in the agreed standard set posed a
challenge for the WG. There was consensus that a balance must be
struck between clinical outcomes and PROMs as well as a compre-
hensive set of outcomes and a standard set that is feasible to meas-
ure. Although there was debate over which outcomes should be
included in the final set, it became clear through the Delphi process
that certain outcomes were essential, e.g. all-cause mortality, cardio-
vascular mortality, ischaemic stroke/systemic embolism/unclassified
stroke, medication side effects, haemorrhagic stroke, life-threatening/
major bleeding, HRQoL, physical functioning, exercise tolerance and
symptom severity.
When evaluating PROMs to be collected as part of the standard
set, consideration was given to the appropriate mix of generic
PROMs and AF-specific PROMs. Some uncertainty surrounds
PROMs in AF, and the methodology to develop robust patient-
reported outcomes was refined in 2013.39 While generic PROMs are
more commonly used, and have been better validated than AF-
specific PROMs, they measure general health and functioning that is
not specific to AF, and scores are influenced by patient demographics
and comorbidities.40 However, AF-specific instruments assess with
high sensitivity domains exclusive and/or relevant to patients with AF,
although they are, in general, less well-validated and may add to the
burden of assessment for patients with other comorbid conditions.41
It is hoped that these tools could be embedded into a provider’s elec-
tronic health record in order to ease adoption of PROMs in routine
clinical practice and reduce the burden on both providers and
patients. It was also important to consider the psychometric and
measurement qualities of the various instruments. Although few
studies of the measurement properties of AF-specific instruments
exist, a recent systematic review has provided useful insights into
their overall utility.41 While the AF-specific instruments recom-
mended in the standard set have been used as outcome measures in
trials, including a recent large randomized trial of catheter ablation
compared to medical therapy in AF,42 they have not yet been used
with the intention of guiding therapy. The WG’s intention in recom-
mending these tools is to support the adoption of AF-specific tools
and to increase awareness and use of these tools to allow further val-
idation and development.
Although the WG was able to reach consensus on the majority of
outcomes to be collected, as well as instruments by which to collect
the outcomes and case-mix variables to allow benchmarking and
comparisons across institutions, one area which remains controver-
sial is how best to collect data on the side effects of prescribed medi-
cation. Although some trials collect data on discontinuation of
medications, there is little granularity to these data.3,44 For example,
it is often not possible to discern whether patients have discontinued
their medication because of a side effect of the medication or
whether they have discontinued their medication because of a per-
ceived lack of effect or a lack of knowledge of the prescribed therapy.
It is also difficult to capture whether patients are taking their medi-
cines according to the prescribed regimen or whether there are inad-
vertent errors with adherence. This is particularly likely to be the
case with oral anticoagulants where complex dosing regimens may
exist.45 The WG would support efforts to improve the evidence
base behind medication side effects in AF.
It is envisaged that the AF standard set could be implemented in a
comprehensive, integrated care model as has been proposed previ-
ously.46 Use of the integrated care approach in AF has been associ-
ated with reduced cardiovascular hospitalizations and all-cause
mortality.47 Nurse-coordinated management could encompass not
only the medical aspects of care but also the education that is vital to
many of the outcomes identified.
There are, of course, limitations to our approach. The standard set
methodology is reliant on the composition of the WGs. Every effort
was made to ensure a balanced global representation of disease
experts allowing for implementation in different healthcare contexts.
Our WG members practice in 11 countries around the world repre-
senting high-, low-, and middle-income countries. Furthermore, since
the standard set was developed with implementation in mind, feasibil-
ity of measuring outcomes was a key concern during the outcome se-
lection stage and therefore not all outcomes could be collected. This
meant that some outcomes could not be included, e.g. burden of AF,
treatment adherence, perceived control over AF, which are never-
theless recognized by the WG as being important.
Implementation of the standard set involves several phases. The
initial phase involves engaging clinical leaders to champion the adop-
tion of the set within their institutions, assessing an institution’s start-
ing point and identifying its goals. This cultivation phase may not be
immediately straightforward, for example particularly if provider re-
imbursement is tied to outcomes. Before such a situation could be
envisaged, risk-adjustment models would require significant analysis
before meaningful algorithms could be developed which carry the
confidence of providers. After the initial phase, a diagnostic phase, in
which current measurement practice and infrastructure is evaluated
to identify gaps preventing the collection of clinical data and PROMs.
It is necessary in this phase to identify at what points data would be
captured and how it would be collected, possibly using electronic
health records. A patient education campaign could be undertaken at
this stage in order to demonstrate, for example, the value of PROMs.
This is likely to increase patient compliance with the additional ques-
tionnaires. To support data collection, a summary of ICD codes for
outcomes included in the standard set that can be coded in this way
was generated (Supplementary material online, Item S4). Pilot studies
would then follow to test strategies for data collection. Incorporating
feedback from these studies, a measurement phase identifies and
adopts the best strategies to relay data back to clinical teams and cur-
rent and future patients.
The WG defined time-points for outcomes measurement that
align with existing clinical time points to minimize the burden on
patients and healthcare professionals.
Conclusions
We have developed a consensus recommendation for a standardized
minimum set of outcomes that are deemed most important to
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.
patients with AF comprising long-term consequences of disease out-
comes, complications of treatment outcomes, and patient-reported
outcomes. This recommendation is targeted for integration into rou-
tine clinical practice and research. Use of the standard set may enable
institutions to monitor, compare, and improve the quality of their
care for patients living with AF.
Supplementary material
Supplementary material is available at European Heart Journal online.
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